The innovative drug industry is coming to a turning point in performance, with 17 listed companies experiencing a year-over-year net profit increase of over 100%.

Data shows that the innovative drug industry will experience a turning point in performance by 2025, with 17 listed companies including Tonghua Dongbao, Sinovac Biotech, and Nanmo Bio seeing net profit growth of over 100% year-on-year. Among them, Tonghua Dongbao achieved a net profit of 1.22B yuan in 2025, a surge of 3005.63% year-on-year. Sinovac Biotech, Nanmo Bio, Sanyuan Guojian, and Zhaoyan New Drug all saw net profit increases of over 300%, while Liaoning Chengda and Shengnuo Bio also achieved growth rates exceeding 200%. In terms of stock price performance, most companies’ stock prices show a positive correlation with performance growth. Tonghua Dongbao has increased by 12.97% since the beginning of this year, Rongchang Biotech has risen over 60%, and WuXi AppTec has increased by over 20.86%. However, some companies’ stock prices performed poorly, such as Sinovac Biotech, which has fallen 20.84% this year, and BeiGene, which has declined 12.58%. (People’s Financial News)